Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 3c, provides guidance

Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q3 EPS of $0.16, $0.03 better than the analyst estimate of $0.13. Revenue for the quarter came in at $702 million versus the consensus estimate of $693.78 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2024 EPS of $0.57-$0.63, versus the consensus of $0.60. Amneal Pharmaceuticals sees FY2024 revenue of $2.7-2.8 billion, versus the consensus of $2.755 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Evercore ISI Starts Credo Tech (CRDO) at Outperform
• Apogee Therapeutics (APGE) call put ratio 1.1 calls to 1 put into share price up before the bell
• SBA Communications (SBAC) call put ratio 1 call to 3.7 puts with a focus on July 175 puts